Compare Adaptive Biotechnologies Corp (ADPT) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sirius XM Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Sirius XM Holdings Inc trades at $30.22 (market cap $10.34B). The key difference: Sirius XM Holdings Inc is far larger — about 3.1× Adaptive Biotechnologies Corp's market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SIRI | |
|---|---|---|
Market Cap | $3.33B | $10.34B |
Sector | Health | Media |
52-Week High | $22.37 | $30.75 |
52-Week Low | $10.24 | $19.92 |
Enterprise Value | $3.19B | $20.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Sirius XM (SIRI) trades at $30.71, up 0.66% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.03 and a net income margin of 9.86%, supported by recent earnings beats. Analysts maintain a consensus Buy rating with a $31.17 price target, and the company continues to generate strong operating cash flow of $1.90B in 2025. Recent news highlights a new advertising partnership with Alphabet and upcoming Q2 2026 earnings.
The outlook for SIRI is positive, driven by consistent earnings performance and strategic partnerships. Key opportunities include dividend yield and potential index inclusion benefits. Risks involve high debt levels and competitive pressures in the media sector. The stock's current price near the consensus target suggests limited upside unless earnings exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
